logo

FBLG

FibroBiologics
--
--(--)
Market Open: --
--
--(--)
Post-Market: --

FBLG Profile

Fibrobiologics, Inc.

An early-stage cell therapy company working on innovative therapies to treat chronic diseases

Pharmaceutical
04/08/2021
01/31/2024
NASDAQ Stock Exchange
13
12-31
Common stock
455 E. Medical Center Blvd., Suite 300, Houston, Texas 77598
--
FibroBiologics, Inc., was originally incorporated as a limited liability company under the laws of Texas on April 8, 2021, and then transformed into a Delaware corporation on December 14, 2021. The Company is a clinical-stage cell therapy company focused on developing and commercializing fibroblast-based therapies for patients with chronic diseases with severe unmet medical needs, including degenerative disc disease, multiple sclerosis, wound healing and certain cancers, as well as potential life-prolonging applications including thymus and spleen convulsion reversal.